CY2027 ESRD Payment Rule: New Low-Volume Billing Tiers

·

On October 28, 2026, CMS issued the Calendar Year 2027 End-Stage Renal Disease Prospective Payment System final rule, CMS-1846-F. It lands two weeks after this blog covered the proposed version, and the finalized numbers bring enough new detail — a restructured low-volume adjustment, a bigger training add-on, and a new AKI billing obligation — to warrant a second look specifically for coding and billing teams.

What CMS Finalized

The rule sets the CY2027 ESRD PPS base rate at $297.52, up from $281.71 in CY2026 — an increase of $15.81 per treatment. Roughly $12.85 of that increase comes from folding oral phosphate binders into the bundled base rate rather than paying for them separately. CMS projects total payments to both hospital-based and freestanding dialysis facilities will rise about 2.7% under the final rule, effective for renal dialysis services furnished on or after January 1, 2027.

None of this changes the HCPCS codes or revenue codes facilities already use to bill ESRD claims. The coding impact is entirely in how payment adjustments, attestations, and documentation requirements interact with those existing codes — which is exactly where billing teams tend to get tripped up on a rule like this.

A Six-Tier Low-Volume Adjustment Replaces the Old Two-Tier System

The low-volume payment adjustment (LVPA) sees the most structural change in the final rule. CMS raised the volume threshold that defines a “low-volume” facility from 4,000 to 8,000 treatments per year, and split what used to be two adjustment tiers into six. That matters for coding and billing teams because facility eligibility and the size of the adjustment now both depend on which of six bands a facility’s treatment count falls into — not a single pass/fail threshold.

  • Facilities with a median treatment volume under 3,000 receive the largest adjuster.
  • Facilities between 7,000 and 7,999 treatments receive the smallest adjuster in the new structure.
  • The attestation deadline for PY2027 LVPA eligibility is December 31, 2026 — before the rule even takes effect.
  • CMS estimates the LVPA changes will move the base rate by about 1.1% (roughly $3), and the policy remains budget-neutral overall.

Billing staff responsible for LVPA attestations should pull current treatment-volume counts now. Facilities near a tier boundary — say, just above or below 8,000 — will see a materially different adjustment than they did under the old two-tier system, and misclassifying a facility’s tier at attestation is the kind of error that surfaces months later as a payment discrepancy.

Training Add-On Payments Rise — and Reach Earlier Into Treatment

The home and self-dialysis training add-on payment increases from $95.60 to $138.00 per training treatment in CY2027. More significantly for coding workflows, CMS finalized a change allowing the training add-on to be billed during the onset period — the first four months of a patient’s dialysis treatment — using an onset adjustment factor of 1.311. Previously, training payments were effectively unavailable during that early window, which meant claims for newly started patients receiving home-dialysis training couldn’t capture the add-on at all.

AKI Beneficiaries Get a New Phosphate Binder Mandate

Starting in CY2027, ESRD facilities must provide medically necessary oral phosphate binders directly to beneficiaries with acute kidney injury under their care, mirroring the ESRD phosphate-binder bundling described above. The AKI dialysis payment rate is set equal to the base rate, $297.52, under section 1834(r) of the Social Security Act. For coding teams, this converts what may have been a pharmacy-billed or patient-obtained medication into a facility responsibility that needs to be reflected in claims and documentation for AKI patients specifically — a population that’s often coded separately from the standing ESRD caseload.

Outlier Thresholds and TDAPA Policy Also Moved

CMS also raised the fixed-dollar-loss and Medicare Allowable Payment amounts used in the outlier policy: the adult fixed-dollar-loss threshold moves from $14.80 to $90.60, and the pediatric threshold from $162.43 to $229.49, driven mainly by projected utilization of new drugs that will qualify as outlier services in 2027. On the drug-payment side, the rule tightens the Transitional Drug Add-on Payment Adjustment (TDAPA) policy: when current average sales price (ASP) data aren’t available, CMS will fall back to older ASP data, and if a manufacturer simply stops reporting ASP, TDAPA or post-TDAPA payment for that drug is discontinued. Coding and revenue-integrity teams that rely on TDAPA-eligible drugs for outlier capture should expect quarterly updates to post-TDAPA add-on amounts rather than a static annual figure.

What This Means Before January 1

None of these changes require new codes or modifiers, which is easy to read as “nothing to do.” In practice, the compliance exposure sits in the attestation and documentation layer around existing codes: LVPA tier attestations are due before the rule takes effect, training-add-on claims for onset-period patients need the new 1.311 factor applied correctly, and AKI claims need to reflect the facility’s new phosphate-binder responsibility. Coding teams that treat this as purely a rate update — rather than a set of attestation and documentation deadlines — are the ones most likely to see denials or rate discrepancies show up in Q1 2027.

The full technical detail, including the rate-calculation methodology and ESRD Quality Incentive Program measure changes, is in CMS’s CY2027 ESRD PPS final rule fact sheet.

Tracking attestation deadlines, tier reclassifications, and documentation changes like these across hundreds of payment rules a year is exactly the kind of work that benefits from automation rather than manual rule-chasing. Medikode’s automated medical coding platform is built to keep coding and billing teams current as rules like CMS-1846-F take effect.